Background: Despite increasing evidence that treat-ing dyslipidemia reduces cardiovascular events, many pa-tients do not achieve recommended lipid targets. Methods: To determine whether showing physicians and patients the patient’s calculated coronary risk can im-prove the effectiveness of treating dyslipidemia in a pri-mary care setting, patients were randomized to receive usual care or ongoing feedback regarding their calcu-lated coronary risk and the change in this risk after life-style changes, pharmacotherapy, or both to treat dyslip-idemia. Outcomes, based on intention-to-treat analysis, included changes in blood lipid levels, coronary risk, and the frequency of reaching lipid targets. Results: Two hundred thirty primary care physicia...
PubMed: 293396912-s2.0-85040780102Objective: A wide gap exists between dyslipidemia guidelines and t...
BACKGROUND: There is nonoptimal adherence of general practitioners (GPs) and patients to cardiovascu...
Lipid-lowering pharmacotherapy reduces morbidity andmortality caused by cardiovascular disease.1 How...
WOS: 000429103400008PubMed ID: 29339691Objective: A wide gap exists between dyslipidemia guidelines ...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
SummaryBackgroundScreening for and management of dyslipidaemia are crucial in primary and secondary ...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
Background: Dyslipidemia, a risk factor for coronary heart disease (CHD), is a burden due to morbidi...
Dyslipidaemia is a common condition managed in general practice. OBJECTIVE: This article reviews the...
Despite significant advances in prevention and treatment, cardiovascular disease continues to be the...
Despite the availability of specific guidelines, the management of dyslipidemia in practice is not o...
PLEASE NOTE: The content of the article was current at the time it was written. The exam for this a...
Objectives and methods: DETECT is a cross-sectional study of 55,518 unselected consecutive patients ...
Objective: Describe the treatment of the patient with atherogenic dyslipidaemia (AD) in routine Prim...
PubMed: 293396912-s2.0-85040780102Objective: A wide gap exists between dyslipidemia guidelines and t...
BACKGROUND: There is nonoptimal adherence of general practitioners (GPs) and patients to cardiovascu...
Lipid-lowering pharmacotherapy reduces morbidity andmortality caused by cardiovascular disease.1 How...
WOS: 000429103400008PubMed ID: 29339691Objective: A wide gap exists between dyslipidemia guidelines ...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
SummaryBackgroundScreening for and management of dyslipidaemia are crucial in primary and secondary ...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
Background: Dyslipidemia, a risk factor for coronary heart disease (CHD), is a burden due to morbidi...
Dyslipidaemia is a common condition managed in general practice. OBJECTIVE: This article reviews the...
Despite significant advances in prevention and treatment, cardiovascular disease continues to be the...
Despite the availability of specific guidelines, the management of dyslipidemia in practice is not o...
PLEASE NOTE: The content of the article was current at the time it was written. The exam for this a...
Objectives and methods: DETECT is a cross-sectional study of 55,518 unselected consecutive patients ...
Objective: Describe the treatment of the patient with atherogenic dyslipidaemia (AD) in routine Prim...
PubMed: 293396912-s2.0-85040780102Objective: A wide gap exists between dyslipidemia guidelines and t...
BACKGROUND: There is nonoptimal adherence of general practitioners (GPs) and patients to cardiovascu...
Lipid-lowering pharmacotherapy reduces morbidity andmortality caused by cardiovascular disease.1 How...